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Abstract
Background: Interferons (IFNs) are potent antiviral cytokines capable of reprogramming the macrophage
phenotype through the induction of interferon-stimulated genes (ISGs). Here we have used targeted RNA
interference to suppress the expression of a number of key genes associated with IFN signalling in murine
macrophages prior to stimulation with interferon-gamma. Genome-wide changes in transcript abundance
caused by siRNA activity were measured using exon-level microarrays in the presence or absence of IFNγ.
Results: Transfection of murine bone-marrow derived macrophages (BMDMs) with a non-targeting
(control) siRNA and 11 sequence-specific siRNAs was performed using a cationic lipid transfection reagent
(Lipofectamine2000) prior to stimulation with IFNγ. Total RNA was harvested from cells and gene
expression measured on Affymetrix GeneChip Mouse Exon 1.0 ST Arrays. Network-based analysis of
these data revealed six siRNAs to cause a marked shift in the macrophage transcriptome in the presence
or absence IFNγ. These six siRNAs targeted the Ifnb1, Irf3, Irf5, Stat1, Stat2 and Nfkb2 transcripts. The
perturbation of the transcriptome by the six siRNAs was highly similar in each case and affected the
expression of over 600 downstream transcripts. Regulated transcripts were clustered based on co-
expression into five major groups corresponding to transcriptional networks associated with the type I
and II IFN response, cell cycle regulation, and NF-KB signalling. In addition we have observed a significant
non-specific immune stimulation of cells transfected with siRNA using Lipofectamine2000, suggesting use
of this reagent in BMDMs, even at low concentrations, is enough to induce a type I IFN response.
Conclusion: Our results provide evidence that the type I IFN response in murine BMDMs is dependent
on Ifnb1, Irf3, Irf5, Stat1, Stat2 and Nfkb2, and that siRNAs targeted to these genes results in perturbation
of key transcriptional networks associated with type I and type II IFN signalling and a suppression of
macrophage M1 polarization.
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Interferons (IFNs) are cytokines capable of causing a
major shift in cellular gene expression through engage-
ment of signal transduction pathways and subsequent
activation of transcriptional networks. IFNs exert their
multiple cellular effects through the induction of inter-
feron-stimulated genes (ISGs) with antiviral, anti-prolifer-
ative and immunomodulatory properties. IFNs have
proven useful clinically not only as potent agents against
both RNA and DNA viruses, but also as response modifi-
ers for oncology and as therapeutic agents for autoim-
mune diseases such as multiple sclerosis [1]. In spite of
this our understanding of the signalling pathways and
transcriptional networks associated with IFN signalling
remains incomplete.
The production of type I IFNs (IFN-α, IFN-β, IFN-ω, IFN-
ε or IFN-κ) is induced both in vitro and in vivo by the acti-
vation of the toll-like receptors (TLRs) [2-4] and other
pathogen sensing systems (e.g. NOD receptors and RNA
helicases RIG-I and MDA-5 [5]) through engagement with
viruses, microbial products or other pro-inflammatory
stimuli. Type I IFNs act through a common cell-surface
receptor composed of two ubiquitously expressed trans-
membrane proteins, IFNAR1 and IFNAR2. IFNγ, the only
type II IFN, shares little sequence homology with the type
I IFNs and binds to a separate receptor complex [6]. Orig-
inally named 'macrophage activating factor', IFNγ is pro-
duced mainly by T-cells and natural killer cells. IFNγ is
capable of inducing direct anti-microbial and anti-tumor
mechanisms, up-regulating antigen presentation and
arresting the cell cycle in macrophages and other cell types
[7]. Macrophages activated by IFNγ are sometimes
referred to as being polarized into an M1 phenotype [8,9].
Macrophages are primed for heightened immune activity
by type I and type II IFNs through the transcriptional reg-
ulation of genes encoding receptors, transcription factors,
cytokines, stress response proteins, immune signalling
molecules and proteins with an anti-infective activity
[10,11], thereby modulating the cell's antiviral and
immuno-regulatory phenotype. Following ligand bind-
ing, engagement of common elements of the JAK-STAT
signalling pathway i.e. Stat1, Stat2, Irf9 [12] and com-
plexes thereof [13], leads to the activation of partially
overlapping gene sets [14-16]. Crosstalk between the two
IFN systems has been proposed as an evolved mechanism
to help defend against a broader spectrum of pathogens
[17], however the complexities of this signalling relation-
ship remain poorly characterized. In this way, type I and
II IFNs exert a pronounced and clinically important effect
upon macrophages, a major effector cell of the innate
immune system. Systems-level studies of macrophage
activation to date have focused on network dynamics and
in silico motif scanning to account the transcriptional
complexity of the stimulated macrophage response [18-
20]. These studies have proved useful in examining the
dynamic nature of the macrophage transcriptome how-
ever they have not addressed specific roles of individual
components within the IFN signalling system.
This study set out to investigate two aspects of the regula-
tion of the macrophage phenotype by interferon. Firstly, a
number of ISGs had been identified from previous exper-
iments within our group as contributing to the protective
effect of IFNγ during viral infection. These genes were
identified from studies using siRNAs to target certain ISGs
in mouse bone marrow derived macrophages (BMDMs)
prior to infection with mouse cytomegalorvirus (mCMV).
We observed significantly increased levels of replication of
mCMV in BMDMs following treatment of the cells with a
number siRNAs (data not shown) however the mecha-
nisms by which the genes targeted contribute to the anti-
viral phenotype are largely unknown. Secondly, we have
been interested in the IFN signalling pathways and the
contribution of a number of cellular transcription factors
to its regulation. We therefore wanted to investigate the
contribution of these factors to the transcriptional
response to IFNγ treatment.
In this study we describe the targeted knockdown of 11
genes using siRNA in BMDMs and the downstream
changes in gene expression caused by specific siRNA activ-
ity as measured using genome-wide, exon-level microar-
rays (for list of genes targeted see Table 1). We chose to
target a range of genes known to be involved in different
aspects of the IFN response (both signalling and antiviral
phenotype) based on the literature and our prior experi-
mental observations [21]. Genes targeted included the
type I IFN cytokine (Ifnb1), transcription factors with
well-known roles in IFN signalling (Irf3, Stat1, Stat2),
addition transcription factors with lesser known roles in
IFN signalling (Nkfb2, Irf5), and a range of IFNγ-induced
genes with known or putative antiviral function (Casp4,
Ifi47, Lyn, Sod2, Traf1). These genes fall both up and
downstream of IFNβ induction according to our knowl-
edge of the IFN pathway [21] and include genes involved
in both the type I and type II response.
By suppressing the expression of these 11 genes we
hypothesized that we would observe varying effects on the
macrophage transcriptome, that when analyzed, would
reveal functional insights into the activity of the encoded
proteins. The study was also designed to provide a frame-
work for beginning to test assumptions about literature
based pathway-constructions [21], to assess the use of
RNA interference as a tool for pathway analysis, and to
test the performance of Affymetrix Exon Array 1.0ST plat-
form. In addition, we have also examined in detail the
non-specific inflammatory effect of siRNA transfection inPage 2 of 17
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reagent (Lipofectamine2000). Our findings highlight
some of the limitations and technical issues associated
with the use of RNAi technology in primary macrophages,
and importantly also provide insights into factors contrib-
uting to the regulation of the transcriptional network
associated with the type I and type II IFN response.
Results
Type I IFN response induced by non-targeting siRNA and 
lipid-carrier
siRNAs and the vectors used to deliver them have previ-
ously been shown to induce non-specific effects in cells
and in particular to activate a type 1 IFN response [22-25].
In order to examine this affect in BMDMs we performed a
series of mock transfections, treating cells for 24 hours
with the cationic lipid reagent Lipofectamine2000 alone
or combined with a non-targeting control siRNA (RISC-
Free siRNA, Thermo Fisher). We used relatively low siRNA
concentrations (20 nM) and low Lipofectamine2000 con-
centrations (0.2%) to replicate optimised experimental
conditions used previously in our lab. All assays were per-
formed in triplicate and total RNA was harvested at 5 and
24 hours post treatment and hybridized to Affymetrix
GeneChip Mouse Exon 1.0 ST Arrays (Figure 1).
We observed a marked up regulation of IFN-inducible
transcripts at both 5 and 24 hours post-transfection of
Lipofectamine2000/RISC-Free siRNA and by
Lipofectamine2000 treatment alone. A total of 571 tran-
scripts were differentially regulated by either of the two
treatment conditions at either time point (ANOVA p <
0.01, fold change > 2). To visualize and further analyse the
transcriptional response to Lipofectamine2000/RISC-Free
siRNA and Lipofectamine2000 only treatments, the net-
work analysis tool Biolayout Express3D [26] was used to
build graphs of the data. This software calculates the Pear-
son correlation between individual transcript profiles by
drawing lines (edges) between genes (nodes) with related
profiles and uses the MCL clustering algorithm [27] to
divide the network into groups of genes with highly corre-
lated expression profiles (for detailed description see
Methods). The differently regulated transcripts could be
divided into four clusters of co-expression (Figure 2a–e)
reflecting different temporal and condition-specific pro-
files (see Additional file 1).
At the 5 hour time point we observed a transient up regu-
lation of pro-inflammatory mediators including tumour
necrosis factor alpha (Tnf) and chemokine Cxcl2 (Mip-
2a) in response to transfection. This early response was
stronger in the Lipofectamine2000/RISC-Free siRNA treat-
ment group, but was also observed by Lipofectamine2000
treatment alone. Genes with an elevated expression at 5
and 24 hours were characteristic of a classic type I IFN
response and included the interferon-inducible proteins
(Ifi202, Ifi205, IIfi202b, Ifih1, Ifit1, Ifit2, Ifit3), members
of the GBP protein family (Gbp1, Gbp2, Gbp3, Gbp5,
Gbp6), antiviral genes (Mx2, Oas1g, Oas2, Oaslg), tran-
scription factors (Stat1, Stat2) and chemokines (Cd40,
Cxcl10, Ccl3, Ccl4). Another class of genes up-regulated at
the 24 hour time point only (including C3, H2-A, H2-
Table 1: Panel of genes targeted by siRNA
siRNA Affymetrix Transcript ID Refseq ID Gene description Relevance to IFNγ response
Casp4 6986649 NM_007609 Caspase 4, apoptosis-related cysteine 
peptidase
pro-apoptotic, IFNγ induced
Ifi47 6780707 NM_010999 Interferon gamma inducible protein 47 IFNγ inducible protein
Ifnb1 6923147 NM_010510 Interferon beta 1, fibroblast IFNγ induced, regulates immune signalling
Irf3 6960326 NM_016849 Interferon regulatory factor 3 virus-induced transcription factor, activates 
IFNα, & IFNβ
Irf5 6945011 NM_012057 Interferon regulatory factor 5 IFNγ induced, transcription factor, activates 
IFNα, IFNβ and plays a role in antiviral 
immunity & apoptosis
Lyn 6911337 NM_001111096 Yamaguchi sarcoma viral (v-yes-1) 
oncogene homolog
tyrosine kinase activity
Nfkb2 6870063 NM_019408 Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 2
DNA-binding sub-unit of NFkB transcription 
factor complex, regulates immune signalling
Sod2 6858344 NM_013671 Superoxide dismutase 2, mitochondrial role in mitochondrial oxidative 
phosphorylation
Stat1 6749376 NM_009283 Signal transducer and activator of 
transcription 1
IFNγ-induced transcription factor, 
modulates IFN responses through signal 
transduction
Stat2 6771641 NM_019963 Signal transducer and activator of 
transcription 2
transcription factor, modulates IFN 
responses through signal transduction
Traf1 6886021 NM_009421 Tnf receptor-associated factor 1 mediates anti-apoptotic signals from TNF 
receptorsPage 3 of 17
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Experimental DesignFigu e 1
Experimental Design. Mouse bone marrow derived monocytes were cultured in the presence of CSF1 conditioned medium 
in six well plates for 7 days in order to allow differentiation into macrophages (BMDM). A series of control transfections were 
performed to assess the effect of Lipofectamine2000 and control RISC-Free siRNA. Six independent wells (on different plates) 
were then treated with either siRNAs targetting the mRNAs of one of 11 genes of interest or control siRNAs. 24 hours later 
three wells of each siRNA treament were stimuated by IFNγ and the cells were harvested 24 hours later. Total RNA was 
extracted and 150 ng labelled using whole transcript labelling and the samples run on Affymetrix mouse exon arrays. Data was 
then subjected to both network and statistical analyses.
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7 day
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Median profiles of co-expressed gene clustersFigure 2
Median profiles of co-expressed gene clusters. Genes regulated by Lipofectamine2000 and RISC-Free siRNA mock trans-
fections (triplicate arrays). For complete gene lists see Additional file 2.
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and Zbp1) and also provided evidence of an a type I IFN
transcriptional response. Over 250 genes were also down-
regulated as part the response, including many cell-cycle
regulators (for full gene lists see Additional file 2). The
gene expression data indicated a substantial shift in the
transcriptome of BMDMs caused by the lipid/RNA-medi-
ated transfection process.
Effect of IFNγ stimulation and sequence-specific siRNA 
transfection on the macrophage transcriptome
We next set out to investigate the effect of
Lipofectamine2000 and targeting siRNA on murine
BMDMs in the presence and absence of IFNγ stimulation.
For these experiments, BMDMs were transfected in tripli-
cate with one of a panel of 11 sequence-specific siRNAs
and left for 24 hours (for a list of genes targeted see Table
1). IFNγ was added to half the samples for a subsequent
24 hours, after which the cultures were harvested (for
experimental overview see Figure 1). RNA extracted from
the samples was subjected to qPCR to evaluate the effi-
ciency of gene knockdown in the presence and absence of
IFNγ (Figure 3a). Where the target mRNA was knocked-
down 30% or more on average in the presence of IFNγ the
samples were taken forward for microarray analysis. In a
number of cases genes of interest did not satisfy this crite-
rion and no further analyses were performed. Total RNA
from samples (in biological triplicates) that met the crite-
ria were labelled and hybridized to Affymetrix GeneChip
Mouse Exon 1.0 ST Arrays. The individual knockdown of
target genes was also evaluated on microarrays at the tran-
script and exon level (Figure 3b and Additional file 3).
In order to assess the sequence-specific effects of siRNAs
on the macrophage transcriptome we first performed a
statistical analysis (for details see Methods). ANOVA anal-
ysis was used to detect statistically significant effects of
siRNA and IFNγ as separate treatments across the entire
data set. 242 transcripts were found to be differentially
regulated between cells treated with RISC-Free siRNA
alone and cells treated with RISC-Free siRNA and stimu-
lated with IFNγ (p < 0.05, fold change > 2). Many genes
up-regulated at 24 hours post-treatment with IFNγ are
known interferon-stimualted genes and markers of a type
II response [7]. These include the chemokines Cxcl9
(MIG) and Ccl2 (MCP-1), the co-activator of MHC class 2
genes (Ciita) and class II MHC components (H2-Aa/Ab1/
DMb2/Ea/Eb2) and interferon regulatory factors (Irf1 and
Irf8). Many other genes involved in antigen presentation
were also up-regulated by IFNγ including components of
the immunoproteasome (Psmb2/8/9/10) and Tap1/2 (for
complete gene lists see Additional file 4). Some of the
genes repressed by IFNγ treatment are known to be asso-
ciated with cell cycle progression, checkpoint control,
DNA synthesis and mitotic spinal formation, although
many others are poorly annotated with little supporting
literature. Overall, these data were consistent with our
previous time-course microarray studies of IFNγ-stimu-
lated BMDMs (available for download from ArrayExpress:
E-MEXP-1490) [21], and with other previously published
reports assessing the transcriptional response to IFNγ
stimulation [15,16,28].
Transcripts regulated by sequence-specific siRNAs were
detected by comparing expression levels between the non-
targeting RISC-Free siRNA controls and each of the indi-
vidual siRNA treatment groups. In the absence of IFNγ
stimulation, 986 transcripts were found to be differen-
tially expressed between the RISC-Free control and any of
the 11 siRNA knock-down groups (p < 0.01, fold change
> 2). In the presence of IFNγ stimulation, 892 transcripts
were detected as differentially expressed following tar-
geted siRNA treatment. 456 transcripts were found to be
commonly affected by siRNA activity in both the absence
and presence of IFNγ in at least one siRNA treatment (for
statistically determined gene lists see Additional files 5, 6,
7).
To visualize and further analyse the transcriptional
response to siRNA and IFNγ treatments, the network anal-
ysis tool Biolayout Express3D was again used to build
graphs of the data. Five prominent clusters of co-expressed
genes were identified from the RNAi data and formed a
network graph containing all genes whose expression lev-
els were altered most significantly by either IFNγ or siRNA
treatments (see Figure 4a). We used a stringent Pearson
cut off threshold of r = 0.9 and clustered the data using a
MCL inflation value (which controls the granularity of
clustering) of 2.2 to ensure minimal genes falling into
these clusters by chance. The process resulted in a conserv-
ative total of 610 genes being included in the final net-
work taken forward for further analysis. Each of the five
major clusters of co-expressed genes that emerged from
the network analysis had a distinctly different expression
profile induced by the RNAi and/or the IFNγ treatment
(Figure 4b–f).
Six siRNAs targeting the transcripts of the genes Ifnb1, Irf3,
Irf5, Stat1, Stat2 and Nfkb2 were found to significantly
perturb the transcriptional activity of primary macro-
phages. These siRNAs had a pronounced effect on the
macrophage transcriptome in both the absence and pres-
ence of IFNγ stimulation, which was not seen in response
to the five other siRNAs used in this study targeting Casp4,
Ifi47, Lyn, Sod2, Traf1 transcripts. Each of the five gene
clusters was mined for Gene Ontology (GO) and KEGG
pathway enrichment to identify significant over represen-
tation of known biological and functional relationships
shared by genes within a cluster using the DAVID online
annotation tool [29]. Mean expression profiles of the clus-Page 6 of 17
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a-b. qPCR and exon-level assessment of gene knockdown by siRNAFigure 3
a-b. qPCR and exon-level assessment of gene knockdown by siRNA. 3a. Percentage mRNA knock-down 48 hours 
after siRNA transfection compared to a control siRNA tagetting the control gene Lamp1. 3b. Example of gene knock-down by 
exon array analysis. Level of knock-down at each of the 23 exon probesets across the entire length of the Nfkb2 transcript in 
the presence of IFNγ. The green line represents the median signal intensity in the three control arrays (RISC-Free) and red line 
the median signal intensity in the three Nfkb2 siRNA knock-down arrays (for other exon-level results see Additional file 3).
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marized in Figure 4a–e and Table 2, respectively.
Description of co-expressed gene clusters
Cluster 1 was the largest cluster in the data set consisting
of 234 genes. The expression of these genes was up-regu-
lated by IFNγ treatment (Figure 3b) and in most cases sup-
pressed by the six siRNAs targeting Ifnb1, Irf3, Irf5, Stat1,
Stat2, Nfkb2, both in presence and absence of IFNγ rela-
tive to the control and other siRNA treatments. Many of
the genes within this cluster are consistent with an inter-
feron signalling response [7] (see Table 2) and have
immunomodulatory properties (Irf1, Stat1/3 Nod1, pro-
teosome components Psmb8/9/10, Tap1/2). GO annota-
tion mining showed them to be enriched in genes
associated with toll-like receptor signalling (mmu04620),
cytokine-cytokine receptor interaction (mmu04060), cell
adhesion molecules (CAMs mmu04514), and JAK-STAT
signalling (mmu04630) pathways. Interestingly, the
genes in this cluster had a spectrum of expression from
those whose expression was markedly up regulated by
IFNγ treatment but little altered by the siRNAs e.g. Cxcl9
and genes associated with MHC class antigen presentation
(Ciita, H2-Aa/Ab1/DMb2/EaEb2), ranging to those
whose expression was only moderately up-regulated by
IFNγ but significantly repressed by the six siRNAs (Ccl2,
a-f. Transcriptional network clustering of expression data from RNAi treated BMDMs – median expression profilesFigu e 4
a-f. Transcriptional network clustering of expression data from RNAi treated BMDMs – median expression 
profiles. A network graph was clustered from microarray data using Pearson correlation r ≥ 0.9 & Markov clustering algo-
rithm (MCL inflation value of 2.2). 4a: Five main clusters of co-expression emerged containing genes influenced most by siRNA 
& IFNγ treatment. A consistent disruption of transcriptional activity of BMDM was observed using six particular siRNAs 
(shaded in blue) targeting Ifnb1, Irf3, Irf5, Nfkb2, Stat1 & Stat2 mRNAs. 4b: Cluster 1 – 234 genes whose expression is induced 
by IFNγ and repressed by the six active siRNAs. 4c: Cluster 2 – 179 genes repressed by IFNγ but de-repressed by six siRNAs. 
4d: Cluster 3 – 67 genes whose expression is not influenced by IFNγ at 24 hour assay point but repressed by six siRNAs. Many 
of these are innate immune response genes 4e: Cluster 4 – 86 genes de-repressed by siRNAs, many of which have known func-
tional association with cell cycle 4f: Cluster 5 – 44 genes enriched with annotation for NF-kB signalling.Page 8 of 17
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opposite ends of the cluster.
Cluster 2 contained a group of 179 genes with opposite
profiles to Cluster 1. Their expression was repressed by
IFNγ treatment but their basal level of expression was up-
regulated when the cells had been treated with siRNAs tar-
geting Ifnb1, Irf3, Irf5, Nfkb2, Stat1, Stat2 (Figure 3d).
This cluster contained a number of negative regulators of
cell growth and proliferation, and was enriched with GO
annotations for biological processes including intracellu-
lar signalling (GO:0007242) and regulation of growth
(GO:0045926). Overall however, the functional roles of
many of the genes composing this cluster are poorly
described.
Cluster 3 contained 67 genes with many known antiviral
or antimicrobial effectors including the 2',5'-oligoade-
nylate synthetases (Oasl1, Oas3), TLR signalling compo-
nents (Tlr3, Myd88), antiviral proteins Mx2, interferon-
inducible genes Isg20, Isg54 (Ifit1) and Isg56 (Ifit2), p-56
related (Ifit) genes and chemokines (Ccl5, Ccl7, Ccl12).
These genes reflected more of a type I IFN antiviral signa-
ture, with most transcripts involved in the innate immune
response (for complete gene lists see Additional file 8).
The expression of such type I IFN-induced transcripts
Table 2: Annotation for co-expressed gene clusters derived from RNAi and IFNγ treatments.
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
Cluster designation IFNγ induced genes IFNγ repressed genes IFNβ induced genes Cell cycle regulators NFkB signalling genes
No. genes in 
cluster 
(Pearson r = 0.9)
234 179 67 86 44
IFNγ treatment 
effect 
(at 24 hr assay 
point)
Up-regulation Repression No effect No significant effect No significant effect
siRNA effect 
(Ifnb1, Irf3/5, Stat1/
2, Nfkb2)
Repression Up-regulation
(De-represssion)
Repression Up-regulation
(De-reprsssion)
Repression
Representative GO 
Terms (p < 0.05)
Immune response, 
Antigen presentation
Intracellular signalling, 
Negative regulation of 
cellular process
Innate immune 
response, 
Inflammatory 
response
Cell cycle, DNA 
metablism, DNA 
replication
Stess response, 
Inflammatory 
response
Enriched KEGG 
pathways (p < 0.05)
TLR signalling, 
Cytokine-cytokine 
receptor, Cell 
adhesion molecules, 
JAK-STAT signalling
- TLR signalling, 
Cytokine-cytokine 
receptor interaction
Cell cycle, DNA 
polymerase, 
Pyrimidine/purine 
metabolism
MAPK signalling, 
Apoptosis
Promoter analysis 
(p < 0.05)
ISRE sequence 
(34/234)
NFkB targets (14/234)
- ISRE sequence (16/67) - NFkB targets (12/44)
CREB targets (4/44)
Representative 
gene membership*
Ccl2, Cxcl9, Cxcl11, 
Vegfa, Il15, Il18, Irf1, 
Irf2, Irf5, Ciita, Stat1, 
Stat3, Gbp1–5, Cd86, 
Itgb7, Cd274, Tlr6, 
Tlr9, Nod1, H2-Aa/
H2-Ab1/Dmb2/Ea
Cd28, Cd33, Cd5l, 
Cdk6, Cebpa, Socs6, 
Igf2, Pfcd4, Dusp7
Isg20, Ifit1, Ifit2, Ifih1, 
Oasl1, Oas3, Mx1/2, 
Myd88, Tlr3, Ccl5, 
Ccl7, Ccl12, Stat2, 
Tnfrsf1a
Ccne1/2 Ccna2, 
Cdc2a, Cdca5, Cdca8, 
Cdc45l, Chek1, Brca1, 
Mcm2/3/4/5/6/7/10
Pola1, Pold1/e/e2
Nfkb1/2, Nfkbia/z, Ikb, 
Il1a/b, Tnf, Cxcl1/2, 
Nos2, Socs3, Tnfaip2/
3
Genes regulated by 
Lipofectamine2000 
& non-specific 
siRNA transfection
52/234
22.2%
10/179
5.6%
46/67
68.7%
69/86
80.2%
10/44
22.7%
*For full gene membership see Supplementarty table 2.Page 9 of 17
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levels of expression for these genes in all IFNγ un-treated
and control RISC-Free samples. This suggested a pre-stim-
ulation of cells occurring due to the transfection process,
resulting in up-regulation of these transcripts. This was
confirmed by the fact that many genes within this cluster
were also up-regulated by Lipofectamine2000 and/or
RISC-Free siRNA transfection in our mock transfection
experiments (46/67 – 68.7%). Interestingly, these genes
did not respond significantly to the subsequent IFNγ stim-
ulus i.e. they were not differentially regulated at 24 hours
post-IFNγ treatment. Furthermore, genes in this cluster
were found to be strongly suppressed by the activity of
Ifnb1, Irf3, Irf5, Stat1, Stat2 and Nfkb2 siRNAs (see figure
4d). In fact this group of genes were the most markedly
effected of any genes in the data set by siRNA treatment
(see Figure 4). This suggested that their expression was
highly dependent on Ifnb1, Irf3, Irf5, Stat1, Stat2 and
Nfkb2.
Cluster 4 contained 86 genes that were either not
expressed or expressed at low levels in control samples,
but were highly expressed (seemingly de-repressed) in
samples treated with Ifnb1, Irf3, Irf5, Stat1, Stat2 and
Nfkb2 siRNAs (especially in the absence of IFNγ treat-
ment). The absolute level of expression of these genes var-
ied greatly between technical replicates, yet the correlation
of expression profiles within the cluster remained high.
Annotation for this cluster was highly enriched with genes
associated with cell cycle progression e.g. (Cdc45l, Cdc6,
Cdca5, Cdca8), cyclins (Ccna2, Ccne1, Ccne2), kinesins
(Kif11, Kif20a, Kif23) and DNA polymerase subunits
(Pola1, Pold1, Pole) (for full list see Additional file 9).
GO categories DNA metabolism (GO:0006259), DNA
replication (GO:0006260), and cell cycle (GO:0007049)
were significantly over-represented in this cluster.
Cluster 5 contained 44 genes whose expression was mildly
elevated by IFNγ treatment and on average subtly down-
regulated by the six siRNAs (i.e. similar to Cluster 1).
However unlike genes in Cluster 1, these genes displayed
a high degree of heterogeneity in expression levels
between replicates, yet still remained highly correlated.
Annotation for this cluster suggested a strong over-repre-
sentation of NF-kB pathway-related genes including NF-
kB transcription factor and signalling components
(Nfkb1, Nfkb2, Nfkbia, Nfkbiz, Ikb) and NF-kB induced
cytokines and chemokines (Tnf, Il1a, Il1b Cxcl1, and
Cxcl2).
Promoter analysis of the five RNAi-derived clusters
Motif scanning for the presence of ISRE (Interferon-Stim-
ulated Response Elements), GAS (Gamma-Activated
Sites) and NF-kB (Nuclear Factor-kappa B) consensus
binding sequences was performed for all 2 kb upstream
promoter regions for genes affected by siRNA activity (see
Methods). Transcription factor target gene databases were
also searched to identify target genes regulated by STAT,
IRF, ISGF3 (Stat1/Stat2/Irf9) or NF-kB transcription factor
complexes (see Methods). The transcriptional regulatory
information was added as annotation classes and tested
for over-representation within the clusters (see Table 2).
This revealed statistically significant over-representation
ISRE promoter sequences for genes within Cluster 1 and
Cluster 3 (p = 0.019 and p = 0.0015, respectively) suggest-
ing direct IFN regulation, and significant over-representa-
tion of NF-kB and CREB target genes in Cluster 5 (p = 4.93
× 10-11 and p = 0.011, respectively) suggesting a JAK-STAT-
independent mechanism of regulation. Clusters 2 and 4
showed no enrichment for these transcription factor bind-
ing sites using these methods.
Overlap of genes affected by mock transfection and 
siRNA/IFNγtreatment
Of the 608 genes derived from the RNAi clusters, a consid-
erable overlap (30.7%,187/608) were also found to be
affected by Lipofectamine2000 treatment and/or transfec-
tion using non-targeting RISC-Free siRNA in the mock
transfections (see Table 2). Overlap between the two data-
sets was most pronounced in Clusters 3 (68.7%, 46/67)
and 4 (80.2%, 69/86). These clusters were associated with
type I IFN activity and cell cycle regulation respectively.
Discussion
In this study we set out to explore a number of questions.
Firstly, our interest in pathways underpinning macro-
phage activation [21] motivated us to want to analyse in
parallel the contribution of a number of known factors to
the IFNγ response in these cells. Secondly, previous RNAi
studies in our laboratory had identified a number of ISGs
as contributing to the enhanced antiviral state of IFNγ-
primed BMDMs to mCMV infection. We reasoned that we
may further our understanding of their mechanism of
action by analysing the affect of their knockdown at the
transcriptional level. Finally, we wished to explore the
potential of using a combination of the recently available
exon level microarrays and improved RNAi targeting capa-
bilities to gain insights into the interferon signalling path-
ways. In order to address these questions, 11 genes were
targeted with siRNAs followed by IFNγ treatment and
microarray analysis on the Affymetrix mouse exon 1.0 ST
array platform. This study provides one of the few reports
investigating the utility of combining RNA interference
with global transcript profiling in macrophages. Our
results highlight the potential of the approach, as well as
some of the associated difficulties in performing this
work.
In carrying out this investigation, we had to contend with
a number of technical issues. The induction of an IFNPage 10 of 17
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an issue in a number of different cell types [23-25,30,31].
This problem is potentially exacerbated in dendritic cells
and macrophages due to their expression of TLRs, RNA
helicases and other pattern recognition receptors involved
in the sensing of pathogen-associated molecular patterns
(PAMPs). The immuno-stimulatory properties of
Lipofectamine2000 and other cationic lipid-based rea-
gents have also been documented previously [32,33]. In
order to minimise these known effects we therefore used
final lipid and siRNA concentrations lower than recom-
mended by the supplier (Thermo Fisher). However as we
observed even these 'mild' transfection conditions still
induced a significant type I IFN response in BMDMs. This
response was characterized by the up-regulation of pro-
inflammatory cytokines, transcription factors and other
IFN-induced genes between 5–24 hours post-transfection
of control siRNA and represented a significant shift in the
transcriptional activity of these cells. The use of of 1,2-dio-
leoyl-3-trimethylammonium-propane (DOTAP) lipid for-
mations to transfect siRNA in mouse cells has also been
shown to induce the type I interferon response [33,34]
and the immuno-stimulatory properties of lipid-based
plasmid DNA transfections are well documented
(reviewed in [35]). Furthermore, we have detected up-reg-
ulation of IFN-induced transcripts in response to Dharma-
fect 1 (Thermo Fisher) 48 hours post treatment of mouse
fibroblasts (NIH-3T3) (unpublished data). These studies
support the notion that IFN stimulation by siRNA and
transfection reagents may be a widespread effect occurring
in a number of different cell types [36].
A second technical issue of our study was the relatively
low and variable knockdown efficiencies achieved when
performing transfections in BMDMs, as measured by
qPCR and array analysis. This was due in part to the low
concentrations of reagents used, but also to the generally
low efficiency of DNA/RNA delivery by transfection to pri-
mary cells such as macrophages. Primary macrophages are
known to be considerably more difficult to transfect than
cultured cell lines [37], making efficient gene knock-
downs difficult to achieve in this study.
Despite these technical issues, we generated high quality
microarray expression data from targeted transfection
studies which was analysed using a combination of con-
ventional statistical and network-based approaches [26].
At the exon level we were unable to observe any convinc-
ing evidence for alternative splicing events between the
comparisons and therefore all further examination of the
data was restricted to gene level analyses. Using network
analysis it was possible to visualise relationships between
differentially regulated transcripts and cluster them into
distinct groups based on the similarity of their expression
profiles across samples.
Network analysis of the data identified five major groups,
or clusters, of co-expressed genes that were regulated by
siRNA treatment. Genes within each cluster were found to
be biologically related according to functional annotation
and transcription factor binding site analysis, and co-reg-
ulated by IFNγ and/or siRNA treatment. The median
expression profiles between clusters were markedly differ-
ent, representing five distinct transcriptional networks.
However, across all clusters, we observed a strong influ-
ence from the activity of six siRNAs targeted to the Ifnb1,
Irf3, Irf5, Stat1, Stat2 and Nfkb2 genes. These siRNAs
induced a global change in the macrophage transcriptome
altering the expression of several hundred downstream
genes. This effect was not observed in response to treat-
ment of the cells with the RISC-free control siRNA or the
other five siRNAs used in this study (targeting the Casp4,
Ifi47, Lyn, Sod2 and Traf1 transcripts). The analyses pre-
sented here suggest that Ifnb1, Irf3, Irf5, Stat1, Stat2 and
Nfkb2 all contribute to the control of genes regulated by
both classes of interferon.
Clusters 1 and 2 in the data set (see Table 2 and Figure 4a–
e) represent genes directly induced or repressed by IFNγ
treatment respectively. Genes within these two clusters
were also influenced by the activity of the Ifnb1, Irf3, Irf5,
Stat1, Stat2 and Nfkb2 siRNAs (to a varying extent). Our
analysis of transcripts regulated by IFNγ stimulation was
consistent with our previous time-course experiments
(ArrayExpress: E-MEXP-1490) and with previous profiling
studies in this area [15,16,28,38]. Genes up-regulated by
IFNγ stimulation (Cluster 1) reflected a broad range of
immunomodulatory function, including an up-regulation
of class II antigen presentation capabilities through the
co-activator of MHC class 2 genes (Ciita), and histocom-
patibility class II antigens. Up-regulation of chemokines,
complement components (C3, C4), caspases (Casp1,
Casp7), interleukins (Il15, Il18) and interferon-induced
proteins was also observed (for complete list see Addi-
tional file 8). In contrast, Cluster 2 contains many genes
that are known to be suppressed by IFNγ stimulation and
whose basal and IFNγ-stimulated expression level
increased following treatment with the six siRNAs relative
to the controls and other siRNA treatments.
Cluster 3 was made up of a group of genes that did not
respond significantly to IFNγ stimulation, but were mark-
edly down-regulated by the activity of the six siRNAs men-
tioned above. Importantly, Cluster 3 contained many well
known type I IFN anti-microbial effector genes encoding
interferon inducible proteins and chemokines suggesting
regulation by IFNβ. Furthermore, statistically significant
over-representation of ISRE promoter sequences in the 5'
flanking regions of these genes, again suggests a depend-
ency on type I IFN regulation and the IFN-induced tran-
scription factor complex, ISGF3. Transcripts withinPage 11 of 17
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dependency on type I IFNs and were the most markedly
down-regulated by siRNA treatment in the dataset. In con-
trast, genes with a dependency on type II IFN i.e. genes
involved in MHC class II antigen presentation [9,39],
were not affected in this same manner by the six siRNAs.
Genes with a co-dependency on both type I and type II
IFN, we believe, are those in the data set being regulated
by both IFNγ and the Ifnb1, Irf3, Irf5, Stat1, Stat2 and
Nfkb2 siRNAs.
Cluster 4 in the data set is made up almost exclusively of
genes whose function can be associated with cell cycle
progression. Many transcripts within Cluster 4 (69/86)
were found to be down-regulated in our mock transfec-
tion experiments during immune stimulation by Lipo-
fectamine and RISC-Free siRNA. This suggests that
transcripts within this cluster, most of which are associ-
ated with cell cycle control, are down regulated or sup-
pressed during macrophage activation. This was
supported by very low expression levels for these tran-
scripts observed in RISC-Free control samples 24 hours
post IFNγ treatment in our second series of experiments.
The expression of genes within this cluster was markedly
induced (or de-repressed) in response to Ifnb1, Irf3, Irf5,
Stat1, Stat2 and Nfkb2 siRNAs (see Figure 4e). This sug-
gests a link between the six genes targeted and the control
of the cell cycle, which we believe may be a secondary
effect of disrupting the IFN pathway. Cluster 5 in the data
set consists of a group of 44 genes, many associated with
the NF-kB signalling system supporting a link between
this system and the IFN pathway in BMDMs [40-42].
Details of this involvement are however ill-defined.
In trying to explain these observations regarding the
Ifnb1, Irf3, Irf5, Stat1, Stat2 and Nfkb2 knockdown phe-
notypes, our hypothesis is that suppression of Ifnb1, Irf3,
Irf5, Stat1, Stat2 and Nfkb2 using siRNA all result in a per-
turbation of the type I IFN response in BMDMs. We
believe this occurs either by a direct perturbation of IFNβ
induction following activation of pathogen detecting sys-
tems (as seen with Irf3, Irf5, Ifnb1 and Nfkb2 siRNAs) or
by perturbation of signalling downstream of the type I
receptor complex (as seen with Stat1 and Stat2 siRNAs).
Perturbation at either of these levels in the pathway, we
believe, is what accounts for the common downstream
alteration of several hundred interferon-regulated tran-
scripts as observed in this study. We also believe the per-
turbation has also influenced NF-kB signalling and
resulted in a modulation of the cell cycle. The common
phenotype induced by Ifnb1, Irf3, Irf5, Stat1, Stat2 and
Nfkb2 siRNAs observed in our study suggests each of the
genes targeted are operating at a similar level or hierarchy
within the interferon pathway, and that suppression of
these genes has a similar effect on the macrophage tran-
scriptome.
We have been modelling the IFN system based on find-
ings reported in the literature [21] and have used this
model to help further interpret the findings of this study
(a simplified version of the model is shown in Figure 5).
As the model indicates, macrophages possess many cell
surface and intracellular receptors for the detection of a
broad range of molecular species specifically found in
pathogenic organisms. It is some of these receptors that
are undoubtedly activated by the transfection reagents/
siRNA. The most likely candidates are those with RNA
binding function such as Ddx58 (RIG-I) and Ifih1 (Mda5)
which detect cytoplasmic viral ssRNA and dsRNA [5,43]
and/or the endosomal TLR receptors namely Tlr3, Tlr7
and Tlr8, that are also activated by these molecules [44]. It
is possible that these receptors may be sensitive to syn-
thetic siRNA in activating the IFN response. Other TLR
receptors e.g. Tlr1/2 and Tlr2/6 that are known to sensitive
to lipopeptides and peptidoglycans might additionally be
activated by the transfection reagent. According to our
model, activation of all of these receptors ultimately leads
to the phosphorylation, dimerization and translocation
of Irf3 and/or Irf7 to the nucleus where they activate Ifnb1
expression. This formation of Irf3:Irf3 and Irf3:Irf7 dimers
is an important regulatory event during the induction of
IFNβ [45] and subsequent up-regulation of ISGs follow-
ing pattern recognition receptor activation [46,47]. There-
fore the suppression Irf3 using siRNA would be expected
to have a strong influence on IFN regulation and subse-
quent downstream ISG expression. Indeed this is what we
observed. In a similar fashion, if the IFNβ (Ifnb1) tran-
script itself was targeted for suppression, it might also be
predicted to have a direct effect on downstream expres-
sion of type I IFN-induced genes (as also observed in this
study). From this perspective, the phenotypes observed in
response to Irf3 and Ifnb1 siRNAs in this study are as
expected.
Stat1 and Stat2 are primary transcriptional regulators of
the IFN response and are essential components of the JAK-
STAT signalling pathway. Their phosphorylation by lig-
and-activated interferon receptors leads them to form the
Stat1-Stat2-Irf9 (ISGF3 complex) which is crucial for the
transcriptional regulation of the IFN response via ISRE
elements [48] following induction of IFNβ. Stat1 also
homodimerizes following activation of the type II IFN
receptor complex to form the Stat1:Stat1 AAF complex to
induce further transcription via GAS sites [12]. The sup-
pression of either Stat1 or Stat2 function would be pre-
dicted to affect IFN signalling directly and alter ISG
expression by preventing transcription factor binding to
ISG promoter sites. Indeed, we have observed a pheno-Page 12 of 17
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Model of known components of the IFN signalling pathway and explanation of observed resultsFigure 5
Model of known components of the IFN signalling pathway and explanation of observed results. Transfection of 
siRNA using Lipofectamine2000 in mouse BMDMs inductes a type I IFN response. This probably occurrs through the activation 
of pattern recognition receptors (PRRs) by dsRNA and/or liposome complexes. Downstream of PRR activation interferon reg-
ulatory factor 3 (Irf3) is phospohorylated and translocates to the nucleus where it which binds to the IFNβ promotor to induce 
expression of the IFNβ transcript (Ifnb1). It has been proposed that interferon regulatory factor 5 (Irf5) contributes in a similar 
manner to induce type I IFN during the antiviral response, and components of the NF-kB pathway are also known to contrib-
ute at this level. Once induced, the IFNβ acts in an autocrine manner to activate JAK-STAT signalling and subsequent formation 
of the interferon-stimulated gene factor 3 (ISGF3), a transcription factor complex composed of Stat1, Stat2 and Irf9 proteins. 
ISGF3 is responsible for driving the expression of type I interferon-stimulated genes via the ISRE (interferon stimulate response 
element) found within the promoter sequence of many ISGs affected in this study. Our data suggest that siRNAs targeted to 
the Ifnb1, Irf3, Irf5, Stat1, Stat2 and Nfkb2 transcripts all disrupt the type I IFN response at a similar level, and therefore alter 
the downstream expression of several hundred IFN-inducible genes in a similar way. Our data also suggest that type I IFN sig-
nalling strongly down-regulates cell cycle genes and influences the activity of the NF-κB signalling and many of the genes associ-
ated with a type II IFNγ response. Subsequent activation by IFNγ influences the expression of a different but significantly 
overlapping set of genes and the magnitude of this response is clearly influenced by the prior activation of the cells by type I sig-
nalling.
BMC Genomics 2009, 10:372 http://www.biomedcentral.com/1471-2164/10/372type consistent with this in our study following Stat1 and
Stat2 suppression using siRNA.
The role of the transcription factor Irf5 in the type I IFN
response is less well established, although recently Paun et
al. has demonstrated that murine Irf5 can be activated by
both TBK1 and MyD88 to form homodimers which bind
to and activate transcription of type I IFN and inflamma-
tory cytokine genes [49]. Perturbation of Irf5 through
siRNA knockdown in this study suggests that Irf5 could
influence type I IFN-induced transcriptional networks at a
similar level to Irf3. Further studies however will be
required to clarify the role Irf5 in this context. Likewise,
the role of Nfkb2 (p52/p100 subunit) in type I IFN signal-
ling is difficult to explain based on the current under-
standing of this protein in the regulation of innate
immunity. Nfkb2 is known to form transcription factor
complexes with RelB and/or Bcl3 as part of the 'alterna-
tive' NF-KB pathway, often associated with B-cell matura-
tion and lymphoid development [50]. Our study strongly
suggests that Nfkb2 may play a central role in the regula-
tion of the type I IFN response in mouse BMDMs, how-
ever this observation is only partially supported in the
literature [41,51]. The presence of NF-kB binding ele-
ments in the IFNβ promoter (enhanceosome) [45] raises
the possibility of a direct interaction of this protein in
IFNβ regulation, however further studies will of course be
necessary to support this hypothesis.
Conclusion
Taken as a whole these data support the idea that many
transcripts are regulated by both the type I and II IFN net-
works and co-stimulation has an additive effect in regulat-
ing their expression. In terms of the involvement of
specific factors in regulating this pathway, then four of the
genes studied here (Ifnb1, Irf3, Stat1 and Stat2) can be
explained based on findings from previous studies and fit
our model of events [21]. However, two genes, Irf5 and
Nfkb2, do not fit this model and our findings indicate that
they may play important but as yet uncharacterised roles
within this pathway. What perhaps is surprising is that the
absolute expression level of all of these factors would
appear to influence the level of type I IFN signalling, indi-
cating a level of co-dependency which we would not nec-
essarily predicted. Furthermore, their marked influence
on type I signalling raises the possibility that these genes
might be targeted in order to suppress this pathway and
ameliorate the non-specific immune-activation caused by
siRNA delivery in vitro or in vivo.
Methods
Cell propagation and differentiation
Primary mouse monocytes were harvested from 10–12
week old male balb/c mouse bone marrow, re-suspended
in DMEM-F12/10% FCS/10% L929 medium and plated
in a 24-well plate at a concentration of 5 × 105 cells/well.
To differentiate the cells from monocytes into primary
macrophages, cells were then cultured for a further 7 days
in DMEM-F12 growth media supplemented with 10%
L929 conditioned medium which contains the macro-
phage stimulating factor CSF-1, with media changes on
days 3 and 5. Flow cytometry was performed on day 6
confirming a double positive cell surface phenotype (>
99%) for F4/80 and CD11b macrophage markers (see
Additional File 9).
Transfection of siRNA and IFNγ treatment
siRNAs (SMARTpools, Thermo Fisher Inc, MA, USA) were
purchased at a 5 nmol scale and redissolved in 1× siRNA
buffer (Thermo Fisher Inc, MA, USA) to a final concentra-
tion of 1 μM. These contained 4 different siRNAs per pool
each designed to target the same transcript. To transfect at
a final concentration of 20 nM, 1 μl of siRNA SMARTpool
was used with 49 μl of Optimem (Invitrogen, CA, USA)
solution while 2 μl of Lipofectamine 2000 (L2K, Invitro-
gen, CA, USA) was mixed with 48 μl Optimem. Following
incubation for 5 min, the siRNA mix was added to the L2K
mix and incubated for a further 30 min, after which 400
μl of DMEM-F12/10% FCS/L929 medium lacking antibi-
otics was added to the siRNA:L2K complexes. Growth
medium was removed and cells were washed in 1× PBS
before 500 μl of the siRNA:L2K liposomes were added.
Cells were then incubated for a further 24 h (37°C, 5%
CO2). For IFNγ treatments, growth medium was replaced
with medium containing 10 U/ml recombinant mouse
IFNγ. Cells were cultured for a further 24 h prior to har-
vesting of total RNA.
RNA extraction & quantitative real time PCR
Total RNA was extracted using an RNeasy Plus kit (Qia-
gen, Hilden, Germany) according to manufacturer's
instructions. RNA was quantified and quality controlled
using a NanoDrop spectrophotometer (NanoDrop Tech-
nologies, DE, USA) and BioAnalyser 2100 (Agilent, CA,
USA). RT-PCR was performed on RNA samples diluted to
10 ng/μl using TaqMan primer/probe sets (Applied Bio-
systems, CA, USA) and Brilliant One-Step q-RT-PCR kit
(Stratagene, CA, USA) according to manufacturer's
instructions. Samples were analysed using a
MXPRO3000P and MXPro software (Stratagene, CA,
USA), respectively. Lamp1 was used as an internal control.
Microarray target labelling and data processing
150 ng of total RNA was processed using the Exon array
target labelling kit (Affymetrix, CA, USA) according to
manufacturer's instructions for small sample labelling but
without the use of the RiboMinus step. Quality control of
microarray data was performed using Affymetrix Expres-
sion Console™ following standard Affymetrix Exon Array
protocols. Data normalisation, statisical and exon-levelPage 14 of 17
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(MO, USA). All probesets from the 'core' set of exons were
imported and normalized using gcRMA. An exon-level
analysis was performed and each siRNA targeted tran-
script was assessed for silencing at the exon-level (sup-
plemetary data). The data was also explored for evidence
of alternative splicing events. Transcript level summariza-
tion was then performed using the mean of all probesets
across each transcript. An expression level filter was
applied to exclude all transcripts with a maximum raw sig-
nal intensity of less than 50 over across all arrays (11,286
transcripts). All microarray data used in this study is avail-
able for download from Gene Expression Omnibus
(GSE14534) Furthermore, the data used for construction
of the networks and the graphs themselves can be down-
loaded (Additional files 10, 11 from journal website).
Statistical Analysis
All experimental conditions employed three biological
replicates and these were used for statistical comparisons
between groups. For mock transfections ANOVA testing
was performed on all filtered probesets comparing
untreated control samples vs. Lipofectamine2000 and vs.
Lipofectamine2000:RISC-Free siRNA at both the 5 and 24
hour time points separately employing a < 0.01 p-value
and > 2 fold change cutoff. For the second set of experi-
ments target specific siRNA effects were detected by
ANOVA between RISC-Free control samples and individ-
ual siRNA knockdown groups (< 0.01 p-value, > 2 fold
change). IFNγ treatment effects were detected by ANOVA
testing between untreated and IFNγ treated RISC-Free con-
trol groups.
Network Analysis of Microarray Data
Tabulated normalised expression data with unique probe
identifiers and annotation (nodeclass) columns was
loaded into the application BioLayout Express3D [26]. An
all-versus-all Pearson correlation matrix was then calcu-
lated based on the expression profile of all filtered probe
sets. Pearson correlations greater than r = 0.7 were stored
and network graphs were constructed at using different
thresholds above this value. Graphs consist of nodes rep-
resenting transcripts connected by edges respresenting
expression correlations above the set threshold. The MCL
algorithm clusters the network graphs according to the
connectivity between nodes as defined by a mathematical
bootstrapping procedure [27]. Network graphs were
explored for clusters of genes whose expression profile
was influenced by siRNA treatment and IFNγ treatment.
The final layout and analysis of the data was performed
using a Pearson correlation cut off of r = 0.9 and the result-
ant graph clustered using an MCL inflation value of 2.2.
To gain an estimate of the statistical significance of a terms
(nodeclasses) represented within a cluster, BioLayout
Express3D uses a two-sided Fisher's exact test in a similar
way to other methods (e.g., GoMiner [51]). A Bonferroni
correction is also used to correct Fisher's p-values for mul-
tiple testing. This approach was used to examine the rep-
resentation of specific regulatory sites assoicated with the
gene clusters.
Transcription factor binding site analysis
2000 bp upstream promoter sequences for all RefSeq
2007 genes were retreived from NCBI and BLAST searched
for the following consensus transcription factor binding
sequences using BioPerl; ISRE – GGAAANNGAAACT [52],
GAS – TTCNNNGAA [53]. Target gene databases queried
for Rel/NF-KB, STAT and IRF bound target genes;
'NFKB.org' – Gilmore Lab, Boston University http://peo
ple.bu.edu/gilmore/nf-kb/target/index.html, 'The Tran-
scriptional Regulatory Element Database', Zhang Lab,
Cold Spring Harbor http://rulai.cshl.edu/cgi-bin/TRED/
tred.cgi?process=searchPromForm and 'Rel/NF-kappaB
target genes' Gosselin, Touzet, Abbadie, Institut de Biolo-
gie de Lille et LIFL http://bioinfo.lifl.fr/NF-KB/.
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